Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

5.05USD
20 Apr 2018
Change (% chg)

$-0.30 (-5.61%)
Prev Close
$5.35
Open
$5.30
Day's High
$5.30
Day's Low
$5.05
Volume
12,122
Avg. Vol
11,613
52-wk High
$5.75
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $54.00
Shares Outstanding(Mil.): 18.00
Dividend: --
Yield (%): --

Financials

  XENE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.67 -- --
ROI: -55.45 1.58 14.38
ROE: -55.50 2.41 16.07

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

07 Mar 2018

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Feb 2018

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

08 Jan 2018

BRIEF-Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank

* XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING

18 Dec 2017

BRIEF-Xenon Pharmaceuticals reports Q3 loss per share $0.43

* Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

Earnings vs. Estimates